These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 8496311)

  • 1. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
    Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: partial response attenuation.
    DeBell WK; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1312-6. PubMed ID: 2026752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
    Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study.
    Chapman IM; Hartman ML; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2874-80. PubMed ID: 8768844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men.
    Hartman ML; Farello G; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1378-84. PubMed ID: 1592884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone.
    Robinson BM; Friberg RD; Bowers CY; Barkan AL
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1121-4. PubMed ID: 1400881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
    Rosenthal SM; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.
    Anderson SM; Shah N; Evans WS; Patrie JT; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):551-60. PubMed ID: 11158008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E2 supplementation selectively relieves GH's autonegative feedback on GH-releasing peptide-2-stimulated GH secretion.
    Anderson SM; Wideman L; Patrie JT; Weltman A; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5904-11. PubMed ID: 11739462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men.
    Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study.
    Jaffe CA; Turgeon DK; Friberg RD; Watkins PB; Barkan AL
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3321-6. PubMed ID: 7593445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.